Provided by Tiger Fintech (Singapore) Pte. Ltd.

Optinose Inc.

9.14
-0.0200-0.22%
Volume:70.48K
Turnover:642.88K
Market Cap:92.06M
PE:-4.31
High:9.19
Open:9.10
Low:9.09
Close:9.16
Loading ...

Press Release: Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 Million

Dow Jones
·
15 Jan

BUZZ-H.C. Wainwright raises OptiNose PT on nasal spray prospects

Reuters
·
03 Jan

Optinose price target adjusted for stock split at H.C. Wainwright

TIPRANKS
·
03 Jan

OptiNose Inc : H.c. Wainwright Raises Target Price to $18 From $5

THOMSON REUTERS
·
03 Jan

OptiNose trading resumes

TIPRANKS
·
31 Dec 2024

OptiNose trading halted, volatility trading pause

TIPRANKS
·
31 Dec 2024

OptiNose trading halted, news pending

TIPRANKS
·
31 Dec 2024

OptiNose to Implement 1-for-15 Reverse Stock Split

MT Newswires Live
·
26 Dec 2024

Optinose announces 1-for-15 reverse stock split

TIPRANKS
·
26 Dec 2024

OptiNose Announces 1-for-15 Reverse Stock Split

THOMSON REUTERS
·
26 Dec 2024

Optinose Announces 1-for-15 Reverse Stock Split

GlobeNewswire
·
26 Dec 2024

OptiNose Third Quarter 2024 Earnings: EPS: US$0.002 (vs US$0.083 loss in 3Q 2023)

Simply Wall St.
·
14 Nov 2024

Optinose Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

Dow Jones
·
13 Nov 2024

OptiNose Inc (OPTN) Q3 2024 Earnings Call Highlights: Revenue Growth Amid Revised Guidance

GuruFocus.com
·
13 Nov 2024

OptiNose Inc : Piper Sandler Cuts Target Price to $1 From $3

THOMSON REUTERS
·
13 Nov 2024

Q3 2024 OptiNose Inc Earnings Call

Thomson Reuters StreetEvents
·
13 Nov 2024

OptiNose Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
12 Nov 2024

OptiNose (OPTN) Reports Break-Even Earnings for Q3

Zacks
·
12 Nov 2024

OptiNose Expects 2024 Xhance Net Revenues Of $75M-$79M Compared To Prior Guidance Of $85M-$90M, With Average Net Revenue Per Prescription To Be Approximately $270, Versus Prior Guidance To Exceed $250

Benzinga
·
12 Nov 2024

OptiNose Q3 2024 GAAP EPS $0.00 Beats $(0.05) Estimate, Sales $20.44M Miss $23.00M Estimate

Benzinga
·
12 Nov 2024